Internal Medicine Alert
RSSArticles
-
Cardiovascular Events Associated with Masked Hypertension and White-coat Hypertension
Analysis from the Dallas Heart Study consisting of 3027 adults revealed that both white-coat hypertension and masked hypertension were independently associated with increased cardiovascular events, and, therefore, home blood pressure monitoring is recommended for U.S. adults, whether symptomatic or asymptomatic.
-
ECG Review: Early Repolarization or Something More?
-
Clinical Briefs
In this section: potential good cardiovascular news; spironolactone best add-on for resistant hypertension; and questions about Vitamin D for primary care practice.
-
Mepolizumab Injection (Nucala)
Mepolizumab is indicated for add-on maintenance treatment of adult patients ≥ 12 years of age with severe asthma and with an eosinophilic phenotype.
-
Carotid Occlusion Rarely Develops from Asymptomatic Carotid Artery Stenosis
Recent study indicates that the risk of progression to carotid occlusion is well below the risk of carotid stenting or carotid endarterectomy.
-
Utility of Non-traditional Risk Factors in Patients Ineligible for Statin Therapy
Adding additional risk factors not in the pooled risk equation to low-risk subjects identified a sub-group with an observed event rate > 7.5% who may warrant statin therapy.
-
Effect of Modified Valsalva Maneuver for Emergency Treatment of Supraventricular Tachycardia
In patients presenting with supraventricular tachycardia, a modified Valsalva maneuver with leg elevation and supine positioning at the end of strain was demonstrated to be more effective than the standard Valsalva maneuver at restoring normal sinus rhythm.
-
Clinical Briefs
In this section: no payoff to physical therapy after healed ankle fracture; bisphosphonates and bone recurrence; and manipulating the microbiome.
-
No More Bacon? Carcinogenicity of Meat
A review of published research by the World Health Organization concludes that processed meats are probably carcinogenic.
-
Naloxone Nasal Spray (Narcan)
The FDA has approved naloxone in the form of a nasal spray as a life-saving medication to reverse the effects of an opioid overdose.